Modulating mitochondrial calcium in cardiac homeostasis and disease
调节心脏稳态和疾病中的线粒体钙
基本信息
- 批准号:10683219
- 负责人:
- 金额:$ 43.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdrenergic AgentsAdultAffectAnimal ModelAnimalsBasic ScienceCalciumCardiacCardiac MyocytesCardiac healthCause of DeathCell DeathClinicalComplexDataDietDiseaseDisease OutcomeDisease ProgressionEFRACEchocardiographyFatty acid glycerol estersFibrosisFunctional disorderFutureGatekeepingGenesGoalsHeartHeart ContractilitiesHeart failureHistologyHomeostasisHypertensionHypertrophyImpairmentKnowledgeLinkLiteratureMapsMeasuresMediatingMetabolic syndromeMethodologyMissionMitochondriaModelingMolecularMultiprotein ComplexesMusMyocardial dysfunctionNG-Nitroarginine Methyl EsterObesityOperative Surgical ProceduresOrganismOutcomeOutcome AssessmentOutcomes ResearchOxidative StressPathologyPermeabilityPhysiologyPlayProductionProteomicsPublic HealthPumpReportingResearchRespirationRoleSecondary toSignal PathwaySignal TransductionSucroseTamoxifenTestingTherapeuticTimeTissuesUnited States National Institutes of HealthVentricular FunctionWorkaorta constrictiondisabilityfunctional declinegenetic manipulationglucose toleranceheart functionimprovedin vivoinnovationinterestmitochondrial permeability transition poremouse modelnovelpreservationpressureprotein complexprotein expressionresponsetherapeutic developmenttherapy developmenttooluptake
项目摘要
Project Summary/Abstract
A leading cause of death worldwide, heart failure is often linked to deficits in energy production in
mitochondria. Mitochondrial uptake of cytosolic Ca2+ plays a critical role in matching energy production to
demand by stimulating ATP production. However, mitochondrial Ca2+ in excess can lead to permeability
transition pore opening and potentially cell death. Animal models of heart failure more closely akin to heart
failure with reduced ejection fraction (HFrEF) are linked to increased mitochondrial Ca2+ in some studies and
decreased mitochondrial Ca2+ in others; even less is known regarding the role of mitochondrial Ca2+ in heart
failure with preserved ejection fraction (HFpEF). With the long-term goal of helping to develop therapies to limit
or restore mitochondrial Ca2+ when appropriate to improve clinical outcomes in HFrEF and HFpEF, this
application will map out the contribution of increased and decreased mitochondrial Ca2+ to cardiac dysfunction
in homeostasis and in mouse models of pressure overload and high fat/high sucrose diet with L-NAME.
Tamoxifen-inducible cardiac-specific deletion of Micu1, the gene encoding the “gatekeeper” of mitochondrial
Ca2+ uniporter complex (mtCU), will be used to induce mitochondrial Ca2+ overload. In the same manner,
deletion of Emre, the gene encoding the essential regulator of the mtCU, will be used to eliminate mtCU
activity and lower mitochondrial Ca2+. The overall objective in this application is to systematically compare the
effects of increased and decreased mitochondrial Ca2+ on measures of cardiac health – mitochondrial function,
tissue histology, contractility before and after stimulation – in homeostasis and in two different types of induced
heart failure. The central hypothesis is that elevated mtCa2+ impairs heart function in homeostasis and in
HFrEF, whereas lowered mtCa2+ has negative effects in energetically demanding states and in HFpEF. The
rationale is that based on the literature and our preliminary data, pressure overload forces the heart to work
harder, elevating mitochondrial Ca2+, while some indications suggest that mice fed the high fat/high sucrose
diet with L-NAME have lower mitochondrial Ca2+. Hence, in the former conditions, increased mitochondrial
Ca2+ is detrimental, and in the latter, decreased mitochondrial Ca2+ is detrimental. The central hypothesis will
be tested by pursuing two specific aims: 1) Assess how elevated and reduced mitochondrial Ca2+ impact
cardiac homeostasis; and 2) Assess how elevated and reduced mitochondrial Ca2+ impact HFrEF and HFpEF-
MetS. This research is conceptually innovative in using genetic manipulation to modulate mitochondrial Ca2+,
and in directly comparing elevated and reduced mitochondrial Ca2+ in models approximating HFrEF and
HFpEF. The outcomes of this research are expected to be significant by establishing a new paradigm
regarding mitochondrial Ca2+ in HFrEF and HFpEF, with the potential to inform future therapeutic strategies.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julia Chang Liu其他文献
Julia Chang Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julia Chang Liu', 18)}}的其他基金
Molecular mechanism and physiological function of mitochondrial calcium regulation
线粒体钙调节的分子机制及生理功能
- 批准号:
10455701 - 财政年份:2020
- 资助金额:
$ 43.83万 - 项目类别:
Molecular mechanism and physiological function of mitochondrial calcium regulation
线粒体钙调节的分子机制及生理功能
- 批准号:
10192800 - 财政年份:2020
- 资助金额:
$ 43.83万 - 项目类别:
Molecular mechanism and physiological function of mitochondrial calcium regulation
线粒体钙调节的分子机制及生理功能
- 批准号:
9370196 - 财政年份:2020
- 资助金额:
$ 43.83万 - 项目类别:
Molecular and physiological analysis of mitochondrial calcium uptake
线粒体钙摄取的分子和生理分析
- 批准号:
9036744 - 财政年份:2015
- 资助金额:
$ 43.83万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 43.83万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 43.83万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 43.83万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 43.83万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 43.83万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 43.83万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 43.83万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 43.83万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 43.83万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 43.83万 - 项目类别: